✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Rigosertib is an investigational drug.
There have been 29 clinical trials for Rigosertib. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Syndrome, and Preleukemia. The leading clinical trial sponsors are Onconova Therapeutics, Inc., Icahn School of Medicine at Mount Sinai, and The Leukemia and Lymphoma Society.
Recent Clinical Trials for Rigosertib
|Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC||Onconova Therapeutics, Inc.||Early Phase 1|
|Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC||Thomas Jefferson University||Early Phase 1|
|Rigosertib for RDEB-SCC||Prof. Johann Bauer||Phase 1/Phase 2|